2016 Q2 Form 10-Q Financial Statement
#000156459016022126 Filed on August 03, 2016
Income Statement
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| Revenue | $19.72M | $11.96M |
| YoY Change | 64.97% | 104.34% |
| Cost Of Revenue | $426.0K | $439.0K |
| YoY Change | -2.96% | 104.19% |
| Gross Profit | $19.30M | $11.52M |
| YoY Change | 67.56% | 104.35% |
| Gross Profit Margin | 97.84% | 96.33% |
| Selling, General & Admin | $12.12M | $9.342M |
| YoY Change | 29.72% | 17.29% |
| % of Gross Profit | 62.79% | 81.11% |
| Research & Development | $5.672M | $3.341M |
| YoY Change | 69.77% | -21.43% |
| % of Gross Profit | 29.39% | 29.01% |
| Depreciation & Amortization | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% |
| % of Gross Profit | 0.52% | 0.87% |
| Operating Expenses | $17.79M | $12.68M |
| YoY Change | 40.27% | 2.02% |
| Operating Profit | $1.508M | -$1.166M |
| YoY Change | -229.33% | -82.28% |
| Interest Expense | -$520.0K | -$770.0K |
| YoY Change | -32.47% | -20.62% |
| % of Operating Profit | -34.48% | |
| Other Income/Expense, Net | -$10.00K | |
| YoY Change | ||
| Pretax Income | $980.0K | -$1.940M |
| YoY Change | -150.52% | -74.3% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | $977.0K | -$1.936M |
| YoY Change | -150.46% | -74.36% |
| Net Earnings / Revenue | 4.95% | -16.19% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | $8.497K | -$17.98K |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding | 115.3M | 107.9M |
Balance Sheet
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $41.80M | $37.00M |
| YoY Change | 12.97% | 8.82% |
| Cash & Equivalents | $41.79M | $37.05M |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.600M | $1.200M |
| YoY Change | 33.33% | -45.45% |
| Inventory | $2.134M | $1.500M |
| Prepaid Expenses | ||
| Receivables | $9.301M | $5.000M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $54.78M | $44.70M |
| YoY Change | 22.55% | 13.35% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $76.00K | $200.0K |
| YoY Change | -62.0% | -32.43% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $24.00K | $3.500M |
| YoY Change | -99.31% | 3922.99% |
| Total Long-Term Assets | $2.060M | $3.700M |
| YoY Change | -44.32% | -25.3% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $54.78M | $44.70M |
| Total Long-Term Assets | $2.060M | $3.700M |
| Total Assets | $56.84M | $48.40M |
| YoY Change | 17.43% | 9.03% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.081M | $2.400M |
| YoY Change | -13.29% | -7.51% |
| Accrued Expenses | $5.833M | $3.000M |
| YoY Change | 94.43% | 84.73% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $18.56M | $12.00M |
| YoY Change | 54.64% | 62.25% |
| Total Short-Term Liabilities | $27.43M | $17.40M |
| YoY Change | 57.67% | 30.81% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $3.744M | $19.40M |
| YoY Change | -80.7% | -29.8% |
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $3.744M | $19.40M |
| YoY Change | -80.7% | -29.8% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $27.43M | $17.40M |
| Total Long-Term Liabilities | $3.744M | $19.40M |
| Total Liabilities | $31.18M | $36.80M |
| YoY Change | -15.28% | -10.11% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$329.5M | |
| YoY Change | ||
| Common Stock | $110.0K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $25.66M | $11.50M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $56.84M | $48.40M |
| YoY Change | 17.43% | 9.03% |
Cashflow Statement
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $977.0K | -$1.936M |
| YoY Change | -150.46% | -74.36% |
| Depreciation, Depletion And Amortization | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% |
| Cash From Operating Activities | $1.600M | -$100.0K |
| YoY Change | -1700.0% | -98.88% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -500.0K | -700.0K |
| YoY Change | -28.57% | 16.67% |
| NET CHANGE | ||
| Cash From Operating Activities | 1.600M | -100.0K |
| Cash From Investing Activities | 0.000 | 0.000 |
| Cash From Financing Activities | -500.0K | -700.0K |
| Net Change In Cash | 1.100M | -800.0K |
| YoY Change | -237.5% | -91.67% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $1.600M | -$100.0K |
| Capital Expenditures | $0.00 | $0.00 |
| Free Cash Flow | $1.600M | -$100.0K |
| YoY Change | -1700.0% | -98.86% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
41789000 | |
| CY2016Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
110594303 | |
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| CY2016Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
9301000 | |
| CY2016Q2 | us-gaap |
Inventory Net
InventoryNet
|
2134000 | |
| CY2016Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1554000 | |
| CY2016Q2 | us-gaap |
Assets Current
AssetsCurrent
|
54778000 | |
| CY2016Q2 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
1960000 | |
| CY2016Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
76000 | |
| CY2016Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
24000 | |
| CY2016Q2 | us-gaap |
Assets
Assets
|
56838000 | |
| CY2016Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2081000 | |
| CY2016Q2 | cort |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
963000 | |
| CY2016Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5833000 | |
| CY2016Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
18557000 | |
| CY2015Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
158000 | |
| CY2016Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
27434000 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
20876000 | |
| CY2016Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
3744000 | |
| CY2015Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
12528000 | |
| CY2016Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
110000 | |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
110000 | |
| CY2016Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
355000000 | |
| CY2016Q2 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
19724000 | |
| CY2016Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.02 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
348796000 | |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
115329000 | |
| CY2016Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-329450000 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-330408000 | |
| CY2016Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
25660000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
18498000 | |
| CY2016Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
56838000 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
51902000 | |
| CY2016Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
280000000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
280000000 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
110481000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
109642000 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
110481000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
109642000 | |
| CY2015Q2 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
11956000 | |
| CY2016Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
426000 | |
| CY2015Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
439000 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5672000 | |
| CY2015Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3341000 | |
| CY2016Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
12118000 | |
| CY2015Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
9342000 | |
| CY2016Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18216000 | |
| CY2015Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
13122000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
1508000 | |
| CY2015Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
770000 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.01 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
107874000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3270000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2977000 | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
1107000 | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
1499000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
11000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
11000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
51000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
97000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3080000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1617000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-388000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-426000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
784000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-200000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
8000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
756000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
474000 | ||
| us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-208000 | ||
| us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
156000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2576000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
631000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-158000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
4000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
4887000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1916000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
34000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-34000 | ||
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
18703000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
3953000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
14750000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
12800000 | ||
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
37048000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates</p> <p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate our estimates and assumptions on an ongoing basis, including those related to revenue recognition, inventory, accrued liabilities including our bonus accrual, clinical trial accruals, stock-based compensation and the timing of payments with respect to our long-term capped royalty obligation, which determines our interest expense. We base our estimates on relevant experience and on other specific assumptions that we believe are reasonable.</p></div> | ||
| us-gaap |
Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
|
<div> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Net Product Sales</p> <p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We primarily sell Korlym directly to patients through Dohmen Life Science Services (Dohmen), a specialty pharmacy. Prior authorization and confirmation of coverage by the patients’ private or government insurance plan or by a third-party charity, such as the National Organization for Rare Disorders (NORD – discussed below), is a prerequisite for Dohmen to ship Korlym. We recognize revenue upon the delivery of our products to these patients.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue from sales of Korlym upon delivery to patients as long as (i) there is persuasive evidence that an arrangement exists between ourselves and the customer, (ii) collectability is reasonably assured and (iii) the price is fixed or determinable. Prior authorization or confirmation of coverage level by the patient’s private insurance plan or government payor is a prerequisite to the shipment of product to a patient. In order to conclude that the price is fixed or determinable, we must be able to (i) calculate gross product revenues from the sales to our customers and (ii) reasonably estimate net product revenues.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2016, we recognize sales to our specialty distributor (SD) at the time of sale to the SD. Before, we did not recognize these sales until the SD had in turn sold to its customers. Sales to the SD were less than two percent of our revenue in the second quarter.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We donate cash to NORD, an independent non-profit organization that helps patients with financial need pay for the treatment of Cushing’s syndrome. We do not include in revenue payments we receive from NORD.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate gross product revenues based on the price we charge our customers. We estimate our net product revenues by deducting from our gross product revenues (a) trade allowances, such as discounts for prompt payment, (b) estimated government rebates and chargebacks, (c) reserves for expected product returns and (d) estimated costs of our patient co-pay assistance program. We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates as new information becomes available.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rebates and Chargebacks:<font style="font-style:normal;">  We contract with Medicaid and other government agencies so that Korlym will be eligible for purchase by, or qualify for partial or full reimbursement from, Medicaid and other government programs. We estimate our rebate and chargeback amounts by applying the discount rates applicable to each government-funded program against our sales to patients covered by such programs.</font></p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Allowances for Patient Assistance Program:<font style="font-style:normal;">  We provide financial assistance to eligible patients whose insurance policies require them to pay high deductibles and co-payments. We calculate the cost of assistance by applying our program guidelines to the eligible sales in the period.</font></p></div> | ||
| CY2016Q2 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
25000 | |
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1998-05-01 | ||
| dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Delaware | ||
| CY2016Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1197000 | |
| CY2015Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
2141000 | |
| CY2016Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
12000 | |
| CY2015Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
3000 | |
| CY2016Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2885000 | |
| CY2015Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2338000 | |
| CY2016Q2 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
4094000 | |
| CY2015Q4 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
4482000 | |
| cort |
Number Of Tablet Manufacturers
NumberOfTabletManufacturers
|
1 | ||
| cort |
Number Of Manufacturers For Mifepristone
NumberOfManufacturersForMifepristone
|
1 | ||
| CY2016Q2 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
2593000 | |
| CY2015Q4 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
1663000 | |
| CY2016Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2555000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1103000 | |
| CY2016Q2 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
111000 | |
| CY2015Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
111000 | |
| CY2016Q2 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
152000 | |
| CY2015Q4 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
69000 | |
| CY2016Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
267000 | |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
220000 | |
| CY2015Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
35000 | |
| CY2016Q2 | cort |
Debt Instrument Payment To Date
DebtInstrumentPaymentToDate
|
21397000 | |
| CY2015Q4 | cort |
Debt Instrument Payment To Date
DebtInstrumentPaymentToDate
|
15087000 | |
| CY2016Q2 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
140000 | |
| CY2016Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
155000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
91000 | |
| cort |
Financing Agreement Covenant Window Period For Royalty Payments From Due Date
FinancingAgreementCovenantWindowPeriodForRoyaltyPaymentsFromDueDate
|
P30D | ||
| CY2016Q2 | us-gaap |
Accretion Expense
AccretionExpense
|
523000 | |
| CY2015Q2 | us-gaap |
Accretion Expense
AccretionExpense
|
737000 | |
| us-gaap |
Accretion Expense
AccretionExpense
|
13700000 | ||
| CY2016Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
45000000 | |
| CY2015Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
45000000 | |
| CY2016Q2 | us-gaap |
Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
|
1277000 | |
| CY2015Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
|
2385000 | |
| cort |
Number Of Stock Option Plans
NumberOfStockOptionPlans
|
2 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
839000 | ||
| CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1656000 | |
| CY2015Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1568000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3270000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2977000 | ||
| CY2016Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
5295000 | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
4600000 |
